Results of coagulation studies on 21 homozygote patients with factor XII (FXII) deficiency revealed that all of them had no cross-reacting material (CRM) in their plasma. The 58 heterozygotes had in every instance an antigen level comparable to that of clotting activity namely, approximately 50% of normal. An analysis of all pertinent literature also showed that the presence of CRM is very rare in FXII deficiency. CRM is present in approximately 5% of homozygote patients. More precisely, seven of 145 patients. Only in one case, the antigen level was normal (FXII Washington). This prevalence appears lower than that observed for another contact phase factor (prekallikrein). The significance of blood abnormal forms of FXII has not been completely clarified yet. Their study appears useful in the attempt of clarifyng the structure-function relation of factor XII.
Colman RW. Contact activation pathway, inflammatory, fibrinolytic, anticoagulant, antiadesive and antiangionetic activation in thrombosis and haemostasis. In: Colman RW, Hirsh J, Marden VJ, et al. (eds).Thrombosis and Hemostasis, IV ed.Philadelphia: Lippincott, Williams and Wilkins, 2001.
2.
Saito H, Kojima Tù. Factors XII, prekallikrein and an high molecular weight kininogen in molecular basis of thrombosis and hemostasis. High KA, Roberts HR (eds). New York: Dekker, 1995.
3.
Ratnoff OD, Colopy IE. A familar hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma. J Clin Invest1955;34:602.
4.
Ratnoff OD. A quarter century with Mr Hageman. Thromb Haemost1980;43:95.
5.
Halbmayer WM, Haushofer A, Schon R, et al.The prevalence of moderate and severe FXII (Hageman factor) deficiency among the normal population evaluation of the incidence of XII deficiency among healthy blood donors. Thromb Haemost1994;71:68.
6.
Girolami A, Randi ML, Gavasso S, et al.The occasional venous thromboses seen in patients with severe/homozygotes) FXII deficiency are due to associated risk factors: A study of the prevalence in 21 patients and review of literature. J Thromb Thrombolysis2004;17:139.
7.
Smink MM, Daniel TM, Ratnoff OD, Stavitsky AB. Immunological demonstration of a deficiency of Hageman factor-like material in Hageman trait. J Lab Med1967;69:819.
8.
Saito H, Scott JG, Movat HZ, Scialla SJ. Molecular heterogeneity of hageman trait (factor XII deficiency): Evidence that two of 49 subjects are cross-reacting material positive (CRM+). J Lab Med1979;94:256.
9.
Girolami A, Patrassi G, De Marco L, Cappellato G.Lack of factor XII antigen in factor XII deficiency as determined by electroimmunoassay. Blut1982;45:141.
10.
Girolami A, Molaro G, Lazzarin M, et al.A new congenital hemorrhagic condition due to the presence of an abnormal factor X (factor X trait), study of a large kindred. Br J Hematol1970;19:179.
11.
Girolami A, Maffei A, Brunetta A, Lazzarin M.Cholecystectomy in a patient with Hegeman trait. Thromb Diath Haem1970;23:449.
12.
Bernardi F, Marchetti G, Volinia S, et al.A frequent factor XII gene mutation in Hegeman trait. Hum Genet1988;80:149.
13.
Hofferbert S, Muller J, Kostering H, et al.A novel 5’ up-stream mutation in the factor XII gene is associated with a Taq 1 restriction site in an Alu repeat in factor XII deficient patients. Hum Genet1996;97:838.
14.
Bernardi F, Marchetti G, Patracchini P, et al.Factor XII gene alteration in Hegeman trait detected by Taq 1 restriction enzyme. Blood1987;69:1421.
15.
Scholsser M, Hofferbert S, Bartz U, et al.The novel acceptor splice site mutation 11396 (G > A) in the factor XII gene causes a truncated trenscript in cross-recting material negative patients. Hum Mol Genet1995;4:1235.
16.
Walsh PN. Factor XII. In: Colman HW, Hirsh I, Marder VJ, et al. (eds).Thrombosis and Hemostasis, IV ed.Philadelphia: Lippincott, Williams, Wilkins, 2001.
17.
Rodeghiero F, Castman G, Ruggeri M, et al.Fibrinolytic studies in 13 unrelated families with factor XII deficiency. Haematologica1991;76:28.
18.
Wuillemin WA, Huber I, Furlan M, Lammle B.Functional characterization of an abnormal factor XII molecule (F XII Bern). Blood1991;78:997.
19.
Kelsey PR, Bottomley F, Grotte GS, Meciver IE. Congenital factor XII deficiency: Successful open heart surgery and anticoagulation. Clin Lab Haemat1985;7:379.
20.
Schved IE, Gris IC, Neven S, et al.Variation of factor XII level during pregnancy in woman with Hegeman factor deficiency. Thromb Haemat1988;60:526.
21.
Miyata T, Kawabata S, Iwanaga S, et al.Coagulation factor XII (Hegeman factor), Washington D.C.: Inactive factor XIIa result from Cys-571> Ser substitution. Proc Natl Acad Sci USA1989;86:8319.
22.
Aznar J, Villa P, Mira Y, et al.Functional anomaly of factor XII. Haemostasis1992;22:345.
23.
Wuillemin WA, Furlan M, Strcker H, Lammle B.Functional characterization of a variant factor XII (XII Locarno) in a cross reacting material positive FXII deficient plasma. Thromb Hemost1992;67:219.
24.
Berettini M, Lammle B, Ciavarella N.Functional and immunological studies on abnormal factor XII in across reactin material positive (CRM+) Factor XII deficiency. Thromb Hemost1985;54:120.
25.
Takahashi I, Saito H.A rapid purification with high recovery of factor XII (Hegman factor) on immunoaffinity column: Application to an abnormal clotting FXII (factor Toronto). J Biochem (Tokyo)1988;103:641.
26.
Hovinga JK, Schaller J, Stricker H, et al.Coagulation factor XII locarno: The functional defect is caused by the amino acid substitution Arg 353-proleading to loss of Kallikrein cleavage site. Blood1994;84:1173.
27.
Krijanovski Y, Proulle V, Mahdi F, et al.Characterization of molecular defect of Fitzerald trait and another novel high-molecular weight kininogen-deficient: Insights into structural requirements for kininogen espression. Blood2003;101:4430.
28.
Saito H, Goodnongh HT, Soria C, et al.Heterogeneity of human prekallikrein (Fletcher trait). Evidence of five of 18 cases are positive for crossreacting material. N Engl J Med1981;305:910.
